Systematic benefit-risk assessment for buprenorphine implant: a semiquantitative method to support risk management

BACKGROUND: Prior to approval in the European Union, a systematic benefit-risk assessment was required to compare buprenorphine implant to sublingual buprenorphine as part of the license application to the European Medicines Agency. OBJECTIVE: The Benefit-Risk Action Team framework was used to descr...

Descripción completa

Detalles Bibliográficos
Autores principales: Osborne, Vicki, Davies, Miranda, Roy, Debabrata, Tescione, Francesco, Shakir, Saad A W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Evidence Synthesis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691701/
https://www.ncbi.nlm.nih.gov/pubmed/32094200
http://dx.doi.org/10.1136/bmjebm-2019-111295

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691701/
https://www.ncbi.nlm.nih.gov/pubmed/32094200
http://dx.doi.org/10.1136/bmjebm-2019-111295

Ejemplares similares